Aadi bioscience announces leadership transition

Los angeles , march 3, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced that brendan delaney has resigned for personal reasons from his position as chief executive officer, president, and member of the board of directors of the company. scott giacobello, currently the company's chief financial officer, has been appointed to serve as interim chief executive officer and president in addition to his current responsibilities.
AADI Ratings Summary
AADI Quant Ranking